Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01413178 Background | Sep 2011 → Mar 2019 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01413178 ↗ |
| Route | Subcutaneous | “Beginning 5 days after the transplant, you will receive filgrastim (G-CSF) through a needle under your skin 1 time each day until your blood cell levels return to normal.” NCT01413178 ↗ |